These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 26084268)
1. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer. Ni Z; Zhang TC J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268 [TBL] [Abstract][Full Text] [Related]
2. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041 [TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809 [TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors. Nagasundaram N; Wilson Alphonse CR; Samuel Gnana PV; Rajaretinam RK J Cell Biochem; 2017 Oct; 118(10):3462-3471. PubMed ID: 28332225 [TBL] [Abstract][Full Text] [Related]
5. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Zhu VW; Cui JJ; Fernandez-Rocha M; Schrock AB; Ali SM; Ou SI Lung Cancer; 2017 Aug; 110():32-34. PubMed ID: 28676215 [TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer. Ni Z; Wang X; Zhang T; Jin RZ Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703 [TBL] [Abstract][Full Text] [Related]
7. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400 [TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib. Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831 [TBL] [Abstract][Full Text] [Related]
9. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422 [TBL] [Abstract][Full Text] [Related]
10. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations. Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596 [TBL] [Abstract][Full Text] [Related]
11. Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. Mathi GR; Kang CH; Lee HK; Achary R; Lee HY; Lee JY; Ha JD; Ahn S; Park CH; Lee CO; Hwang JY; Yun CS; Jung HJ; Cho SY; Kim HR; Kim P Eur J Med Chem; 2017 Jan; 126():536-549. PubMed ID: 27915169 [TBL] [Abstract][Full Text] [Related]
12. Insight on mutation-induced resistance to anaplastic lymphoma kinase inhibitor ceritinib from molecular dynamics simulations. He MY; Li WK; Meiler J; Zheng QC; Zhang HX Biopolymers; 2019 Feb; 110(2):e23257. PubMed ID: 30664251 [TBL] [Abstract][Full Text] [Related]
13. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites. Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558 [TBL] [Abstract][Full Text] [Related]
14. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013 [TBL] [Abstract][Full Text] [Related]
15. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571 [TBL] [Abstract][Full Text] [Related]
16. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591 [TBL] [Abstract][Full Text] [Related]
17. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559 [TBL] [Abstract][Full Text] [Related]
18. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer. Ai X; Shen S; Shen L; Lu S Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414 [TBL] [Abstract][Full Text] [Related]
19. Insight into crizotinib resistance mechanisms caused by three mutations in ALK tyrosine kinase using free energy calculation approaches. Sun H; Li Y; Li D; Hou T J Chem Inf Model; 2013 Sep; 53(9):2376-89. PubMed ID: 23952683 [TBL] [Abstract][Full Text] [Related]
20. Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs. Li J; Liu W; Luo H; Bao J J Mol Model; 2016 Sep; 22(9):231. PubMed ID: 27585676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]